Sign up here for GlobalData's free bi-weekly Covid-19 report on the latest information your industry needs to know.AstraZeneca partnered with Shenzhen Kangtai Biological Products to manufacture its Covid-19 vaccine candidate in mainland China, marking its first deal to supply in the country.
As part of the deal, Shenzhen Kangtai will have an annual production capacity of at least 100 million doses of the vaccine candidate, AZD1222.
The vaccine candidate, developed the University of Oxford, UK, is licensed to AstraZeneca, which is working to boost access to the product via multiple supply deals.
Shenzhen Kangtai must have the capacity to manufacture at least 200 million doses by the end of next year, under the exclusive framework agreement,.